Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:04:45 ON 24 MAY 2002

=> file medline, biosis, dgene, embase, jicst, japio, frosti, fsta, uspatful

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 15:05:32 ON 24 MAY 2002

FILE 'BIOSIS' ENTERED AT 15:05:32 ON 24 MAY 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'DGENE' ENTERED AT 15:05:32 ON 24 MAY 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 15:05:32 ON 24 MAY 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'JICST-EPLUS' ENTERED AT 15:05:32 ON 24 MAY 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'JAPIO' ENTERED AT 15:05:32 ON 24 MAY 2002
COPYRIGHT (C) 2002 Japanese Patent Office (JPO)

FILE 'FROSTI' ENTERED AT 15:05:32 ON 24 MAY 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:05:32 ON 24 MAY 2002
COPYRIGHT (C) 2002 International Food Information Service

FILE 'USPATFULL' ENTERED AT 15:05:32 ON 24 MAY 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s insulin ailment

L1 0 INSULIN AILMENT

=> s insulin

L2 630045 INSULIN

=> s l2 and ailment or disease

4 FILES SEARCHED...
L3 6519258 L2 AND AILMENT OR DISEASE

=> s non-peptidyl compound

L4 33 NON-PEPTIDYL COMPOUND

=> s l4 and method

L5 33 L4 AND METHOD

=> s l5 and l3

L6 26 L5 AND L3

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 26 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
TI Anti-obesity and insulin sensitizing effects of small molecule insulin receptor activators.

ACCESSION NUMBER: 2001:458806 BIOSIS
DOCUMENT NUMBER: PREV200100458806
TITLE: Anti-obesity and insulin sensitizing effects of small molecule insulin receptor activators.
AUTHOR(S): Strowski, Mathias Z. (1); Air, Ellen; Salituro, Gino M.; Liu, Kun; Woods, Stephen C.; Zhang, Bei B.
CORPORATE SOURCE: (1) Rahway, NJ USA
SOURCE: Diabetes, (June, 2001) Vol. 50, No. Supplement 2, pp. A275.
print.
Meeting Info.: 61st Scientific Sessions of the American Diabetes Association Philadelphia, Pennsylvania, USA June 22-26, 2001
ISSN: 0012-1797.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L6 ANSWER 2 OF 26 USPATFULL
TI Compounds and methods for modulating junctional adhesion molecule-mediated functions
AB Methods for using modulating agents to enhance or inhibit junctional adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. The modulating agents comprise at least one JAM cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the JAM cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

ACCESSION NUMBER: 2002:116254 USPATFULL
TITLE: Compounds and methods for modulating junctional adhesion molecule-mediated functions
INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA
Symonds, James Matthew, Ottawa, CANADA
Gour, Barbara J., Kemptville, CANADA
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Ottawa, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6391855	B1	20020521	
APPLICATION INFO.:	US 1999-324541		19990602	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: DeCloux, Amy
LEGAL REPRESENTATIVE: SEED Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 2338

L6 ANSWER 3 OF 26 USPATFULL
TI Piperidine compounds
AB Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical

compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antiviral materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidaseactivity are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:88641 USPATFULL
TITLE:	Piperidine compounds
INVENTOR(S):	Kim, Choung U., San Carlos, CA, United States Williams, Matthew A., Foster City, CA, United States
PATENT ASSIGNEE(S):	Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6376674	B1	20020423
APPLICATION INFO.:	US 1999-376995		19990818 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-955564, filed on 17 Oct 1997, now patented, Pat. No. US 5994377 Continuation-in-part of Ser. No. US 1996-735285, filed on 21 Oct 1996, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-28901P	19961021 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Davis, Zinna Northington
LEGAL REPRESENTATIVE:	Bosse, Mark L.
NUMBER OF CLAIMS:	2
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	4820

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 26 USPATFULL

TI Biologically active compounds and methods of constructing and using the same

AB A **method** of constructing biologically active compounds which mimic the biological activity of the biologically active protein block the activity of the biologically active protein is disclosed. A **method** of identifying specific and discrete portions of pathogen antigens which either serve as epitopes for neutralizing antibodies or which are involved in pathogen binding to host cell receptors is disclosed. A **method** of constructing biologically active compounds which compete with cellular receptors for binding to either biologically active proteins or pathogen antigens is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:81606 USPATFULL
TITLE:	Biologically active compounds and methods of constructing and using the same
INVENTOR(S):	Greene, Mark I., Penn Valley, PA, United States Williams, William V., Havertown, PA, United States Weiner, David B., Merion, PA, United States Cohen, Jeffrey A., Solon, OH, United States Kieber-Emmons, Thomas, Newtown Square, PA, United States Williams, Robert M., Fort Collins, CO, United States
PATENT ASSIGNEE(S):	The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	[redacted] 6372884	B1	20020416
APPLICATION INFO.:	US 1996-752816		19961121 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-940654, filed on 3 Sep 1992, now patented, Pat. No. US 5637677 Continuation-in-part of Ser. No. US 1991-702833, filed on 20 May 1991, now abandoned Continuation of Ser. No. US 1989-326328, filed on 21 Mar 1989, now abandoned Continuation-in-part of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned Continuation-in-part of Ser. No. US 1990-462542, filed on 9 Jan 1990, now abandoned Division of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned Continuation-in-part of Ser. No. US 1991-648303, filed on 25 Jan 1991, now abandoned Continuation of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned Continuation-in-part of Ser. No. US 1991-685881, filed on 15 Apr 1991, now abandoned Continuation of Ser. No. US 1990-574391, filed on 27 Aug 1990, now abandoned Continuation of Ser. No. US 1988-194026, filed on 13 May 1988, now patented, Pat. No. US 4962510 Continuation-in-part of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned Continuation-in-part of Ser. No. US 1990-583626, filed on 14 Sep 1990, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Burke, Julie
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 43 Drawing Page(s)
LINE COUNT: 2624
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 26 USPATFULL
TI Process for determining the agonist or antagonist of galanin receptor (GALR3)
AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:75211 USPATFULL
TITLE: Process for determining the agonist or antagonist of galanin receptor (GALR3)
INVENTOR(S): Bard, Jonathan A., Doylestown, PA, United States
Borowsky, Beth, Montclair, NJ, United States
Smith, Kelli E., Wayne, NJ, United States
Branchek, Theresa A., Teaneck, NJ, United States
Gerald, Christophe P. G., Ridgewood, NJ, United States

PATENT ASSIGNEE(S): Jones, Kenneth A., Bergenfield, NJ, United States
Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6368812	B1	20020409
APPLICATION INFO.:	US 1998-58333		19980409 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1997-US18222, filed on 9 Oct 1997 Continuation-in-part of Ser. No. US 1997-900230, filed on 23 Jul 1997 Continuation-in-part of Ser. No. US 1997-787261, filed on 24 Jan 1997, now abandoned Continuation-in-part of Ser. No. US 1996-767964, filed on 17 Dec 1996, now abandoned Continuation-in-part of Ser. No. US 1996-728139, filed on 9 Oct 1996, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Pak, Michael
LEGAL REPRESENTATIVE: White, John P., Cooper & Dunham LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 5216
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 26 USPATFULL
TI Compounds and methods for modulating nonclassical cadherin-mediated functions
AB Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:57757 USPATFULL
TITLE: Compounds and methods for modulating nonclassical cadherin-mediated functions
INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA
Gour, Barbara J., Montreal, CANADA
PATENT ASSIGNEE(S): Adherex Technologies, Ottawa, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358920	B1	20020319
APPLICATION INFO.:	US 1998-187859		19981106 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-73040, filed on 5 May 1998
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Allen, Marianne P.
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 236
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 26 USPATFULL
TI Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
AB This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: ##STR1##

In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:202393 USPATFULL
TITLE:	Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
INVENTOR(S):	Gerald, Christophe P. G., Ridgewood, NJ, United States Weinshank, Richard L., Teaneck, NJ, United States Walker, Mary W., Elmwood Park, NJ, United States Branchek, Theresa, Teaneck, NJ, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316203	B1	20011113
APPLICATION INFO.:	US 1998-200673		19981125 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-566096, filed on 1 Dec 1995, now patented, Pat. No. US 5968819 Continuation-in-part of Ser. No. US 1994-349025, filed on 2 Dec 1994, now patented, Pat. No. US 5602024, issued on 11 Feb 1997		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Kunz, Gary L.
ASSISTANT EXAMINER:	Gucker, Stephen
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	45 Drawing Figure(s); 40 Drawing Page(s)
LINE COUNT:	4363

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 26 USPATFULL
TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such

vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:158027 USPATFULL
TITLE:	DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
INVENTOR(S):	Salon, John A., Montclair, NJ, United States Laz, Thomas M., Parlin, NJ, United States Nagorny, Raisa, Fair Lawn, NJ, United States Wilson, Amy E., New York, NY, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6291195	B1	20010918
APPLICATION INFO.:	US 2000-478602		20000106 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-224426, filed on 31 Dec 1998		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Spector, Lorraine
ASSISTANT EXAMINER:	O'Hara, Eileen B.
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT:	2920

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 26 USPATFULL

TI DNA encoding galanin GALR3 receptors and uses thereof

AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:152696 USPATFULL
TITLE:	DNA encoding galanin GALR3 receptors and uses thereof
INVENTOR(S):	Bard, Jonathan A., Doylestown, PA, United States Borowsky, Beth, Montclair, NJ, United States Smith, Kelli E., Wayne, NJ, United States Branchek, Theresa A., Teaneck, NJ, United States Gerald, Christophe P. G., Ridgewood, NJ, United States Jones, Kenneth A., Bergenfield, NJ, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	[redacted] 6287788	B1	20010911
APPLICATION INFO.:	US 1998-199737		19981125 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1997-US18222, filed on 9 Oct 1997 Continuation-in-part of Ser. No. US 1997-900230, filed on 23 Jul 1997 Continuation-in-part of Ser. No. US 1997-787261, filed on 24 Jan 1997, now abandoned Continuation-in-part of Ser. No. US 1996-767964, filed on 17 Dec 1996, now abandoned Continuation-in-part of Ser. No. US 1996-728139, filed on 9 Oct 1996, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Pak, Michael
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 4441
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 26 USPATFULL

TI DNA ENCODING GALANIN GALR3 RECEPTORS AND USES THEREOF

AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:119145 USPATFULL
TITLE: DNA ENCODING GALANIN GALR3 RECEPTORS AND USES THEREOF
INVENTOR(S): BARD, JONATHAN A., DOLYTOWN, PA, United States
BOROWSKY, BETH, MONTCLAIR, NJ, United States
SMITH, KELLI E., WAYNE, NJ, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001009766	A1	20010726
	US 6329197	B2	20011211
APPLICATION INFO.:	US 1997-900230	A1	19970723 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-787261, filed on 24 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-767964, filed on 17 Dec 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-728139, filed on 9 Oct 1996, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: COOPER & DUNHAM, 1185 AVE OF THE AMERICAS, NEW YORK, NY, 10036
NUMBER OF CLAIMS: 211
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 4388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 26 USPATFULL

TI Insulin-like growth factor agonist molecules
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:97888 USPATFULL
TITLE:	Insulin-like growth factor agonist molecules
INVENTOR(S):	Clark, Ross G., Auckland, New Zealand Lowman, Henry B., El Granada, CA, United States Robinson, Iain C. A. F., St. Albans, United Kingdom
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251865	B1	20010626
APPLICATION INFO.:	US 1998-52888		19980331 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Romeo, David
LEGAL REPRESENTATIVE:	Hasak, Janet E.
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT:	4925

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 26 USPATFULL
TI Peptides and peptidomimetics with structural similarity to human P53 that activate P53 function
AB The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and to select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:86587 USPATFULL
TITLE:	Peptides and peptidomimetics with structural similarity to human P53 that activate P53 function
INVENTOR(S):	Halazonetis, Thanos, Philadelphia, PA, United States Hartwig, Wolfgang, Stamford, CT, United States
PATENT ASSIGNEE(S):	Bayer Corporation, Westhave, CT, United States (U.S. corporation) The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6245886	B1	20010612	
	WO 9625434		19960822	
APPLICATION INFO.:	US 1997-894327		19971204	(8)
	WO 1996-US1535		19960216	
			19971204	PCT 371 date
			19971204	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-392542, filed

on 16 Feb 1995, now patented, Pat. No. US 6169073

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Huff, Sheela
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1305
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 26 USPATFULL
TI Compounds and methods for synthesis and therapy
AB Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:63718 USPATFULL
TITLE: Compounds and methods for synthesis and therapy
INVENTOR(S): Bischofberger, Norbert W., San Carlos, CA, United States
Kim, Choung U., San Carlos, CA, United States
Lew, Willard, San Mateo, CA, United States
Liu, Hongtao, Foster City, CA, United States
Williams, Matthew A., Foster City, CA, United States
PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6225341	B1	20010501
APPLICATION INFO.:	US 1999-288091		19990408 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-606624, filed on 26 Feb 1996, now patented, Pat. No. US 5952375 Continuation-in-part of Ser. No. US 1995-580567, filed on 29 Dec 1995, now abandoned Continuation-in-part of Ser. No. US 1995-476946, filed on 6 Jun 1995, now patented, Pat. No. US 5866601 Continuation-in-part of Ser. No. US 1995-395245, filed on 27 Feb 1995, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lambkin, Deborah C.
LEGAL REPRESENTATIVE: Bosse, Mark L.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 11195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 26 USPATFULL
TI DNA encoding SNORF25 receptor
AB This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides

complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:59682 USPATFULL
TITLE:	DNA encoding SNORF25 receptor
INVENTOR(S):	Bonini, James A., Oakland, NJ, United States Borowsky, Beth E., Montclair, NJ, United States Adham, Nika, Ridgewood, NJ, United States Boyle, Noel, Cliffside Park, NJ, United States Thompson, Thelma O., Passaic Park, NJ, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221660	B1	20010424
APPLICATION INFO.:	US 1999-387699		19990813 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-255376, filed on 22 Feb 1999		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Spector, Lorraine
ASSISTANT EXAMINER:	O'Hara, Eileen B.
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS:	21
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT:	2877

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 26 USPATFULL

TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:59638 USPATFULL
TITLE:	DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
INVENTOR(S):	Salon, John A., Montclair, NJ, United States Laz, Thomas M., Parlin, NJ, United States Nagorny, Raisa, Fair Lawn, NJ, United States Wilson, Amy E., New York, NY, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221616	B1	20010424
APPLICATION INFO.:	US 2000-478601		20000106 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-224426, filed on 31 Dec 1998

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: O'Hara, Eileen B.
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2882
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 26 USPATFULL
TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:59635 USPATFULL
TITLE: DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
INVENTOR(S): Salon, John A., Montclair, NJ, United States
Laz, Thomas M., Parlin, NJ, United States
Nagorny, Raisa, Fair Lawn, NJ, United States
Wilson, Amy E., New York, NY, United States
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221613	B1	20010424
APPLICATION INFO.:	US 1998-224426		19981231 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: O'Hara, Eileen B.
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 26 USPATFULL
TI Synthesis and use of .alpha.-ketoamide derivatives and arrays
AB The invention is based on new methods for making and using compounds and

arrays of novel .alpha.-ketoamides, and the arrays and compounds made by these methods. These novel compounds are potential inhibitors of proteolytic enzymes, particularly cysteine proteases such as cruzain. Application of the new methods has led to the identification of a number of new inhibitors, from amongst an array of about 38,000 .alpha.-ketoamide derivatives, having specific activity against three cysteine proteases: cruzain, papain, and cathepsin B. These compounds and other compounds identified by the methods described herein can be useful, for example, in developing pharmaceutic agents for the treatment of diseases (e.g., Chagas' **disease**) associated with these proteases. Although the disclosed compounds have specific activity for cruzain, papain, cathepsin B, the methods described herein can also be used to identify inhibitors of other proteases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:150348 USPATFULL
TITLE:	Synthesis and use of .alpha.-ketoamide derivatives and arrays
INVENTOR(S):	Baldino, Carmen M., Lexington, MA, United States Coffen, David L., Cambridge, MA, United States Chipman, Stewart D., Reading, MA, United States Cheng, Hong, Brighton, MA, United States
PATENT ASSIGNEE(S):	ArQule, Inc., Medford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6143931		20001107	
APPLICATION INFO.:	US 1998-61752		19980416	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-44768P	19970416	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Lukton, David
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	11
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT:	954

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 26 USPATFULL

TI Compounds and methods for modulating tissue permeability

AB Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase vasopermeability. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:113775 USPATFULL

TITLE: Compounds and methods for modulating tissue permeability

INVENTOR(S): [redacted]aschuk, Orest W., Westmount, C[redacted]ada
Symonds, James Matthew, Ottawa, Canada
Gour, Barbara J., Kemptville, Canada

PATENT ASSIGNEE(S): Adherex Technologies Inc., Ottawa, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6110747		20000829
APPLICATION INFO.:	US 1998-222373		19981229 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-1511, filed on 31 Dec 1997

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davenport, Avis M.
LEGAL REPRESENTATIVE: Seed IP Law Group PLLC
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 2887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 26 USPATFULL
TI Piperidine compounds
AB Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:155760 USPATFULL
TITLE: Piperidine compounds
INVENTOR(S): Kim, Choung U., San Carlos, CA, United States
Williams, Matthew A., Foster City, CA, United States
PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994377		19991130
APPLICATION INFO.:	US 1997-955564		19971017 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-735385, filed on 21 Oct 1996

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-28901P	19961021 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davis, Zinna Northington
LEGAL REPRESENTATIVE: Bosse, Mark L.
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
LINE COUNT: 4903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 26 USPATFULL
TI Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
AB This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has the structure: ##STR1## In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:151023 USPATFULL
TITLE:	Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
INVENTOR(S):	Gerald, Christophe P. G., Ridgewood, NJ, United States Weinshank, Richard L., Teaneck, NJ, United States Walker, Mary W., Elmwood Park, NJ, United States Branchek, Theresa, Teaneck, NJ, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5989920		19991123
APPLICATION INFO.:	US 1996-668650		19960604 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-566096, filed on 1 Dec 1995 which is a continuation-in-part of Ser. No. US 1994-349025, filed on 2 Dec 1994, now patented, Pat. No. US 5602024

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Caputa, Anthony C.
ASSISTANT EXAMINER:	Gucker, Stephen
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS:	15
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	47 Drawing Figure(s); 42 Drawing Page(s)
LINE COUNT:	5364

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 26 USPATFULL
TI **Method** of identifying ligands which bind recombinant galanin receptor (GALR2)
AB This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising an isolated nucleic acid encoding a galanin receptor, cells comprising such vectors, antibodies directed to the galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding galanin receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid encoding a galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant galanin receptor, as well as methods of determining binding of compounds to the

galanin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:132514 USPATFULL
TITLE:	**Method** of identifying ligands which bind recombinant galanin receptor (GALR2)
INVENTOR(S):	Smith, Kelli E., Wayne, NJ, United States Gerald, Christophe P. G., Ridgewood, NJ, United States Weinshank, Richard L., Teaneck, NJ, United States Linemeyer, David, Westfield, NJ, United States Branchek, Theresa, Teaneck, NJ, United States Forray, Carlos, Paramus, NJ, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972624		19991026
APPLICATION INFO.:	US 1996-626685		19960401 (8)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-590494, filed on 24 Jan 1996, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Feisee, Lila
ASSISTANT EXAMINER:	Pak, Michael
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT:	2695

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 26 USPATFULL

TI DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

AB This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: ##STR1## In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:128435 USPATFULL
TITLE:	DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
INVENTOR(S):	Gerald, Christophe P. G., Ridgewood, NJ, United States Weinshank, Richard L., Teaneck, NJ, United States Walker, Mary W., Elmwood Park, NJ, United States Branchek, Theresa, Teaneck, NJ, United States
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 5968819 19991019
APPLICATION INFO.: US 1995-566096 19951201 (8)
RELATED APPLN. INFO.: [redacted]ntinuation-in-part of Ser. No. [redacted] 1994-349025, filed on 2 Dec 1994, now patented, Pat. No. US 5602024

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Duffy, Patricia
ASSISTANT EXAMINER: Gucker, Stephen
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham Llp
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 45 Drawing Figure(s); 40 Drawing Page(s)
LINE COUNT: 4657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 26 USPATFULL
TI Compounds and methods for synthesis and therapy
AB Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:110364 USPATFULL
TITLE: Compounds and methods for synthesis and therapy
INVENTOR(S): Bischofberger, Norbert W., San Carlos, CA, United States
Kim, Choung U., San Carlos, CA, United States
Lew, Willard, San Mateo, CA, United States
Liu, Hongtao, Foster City, CA, United States
Williams, Matthew A., Foster City, CA, United States
PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5952375		19990914
APPLICATION INFO.:	US 1996-606624		19960226 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-580567, filed on 29 Dec 1995, now abandoned which is a continuation-in-part of Ser. No. US 1995-476946, filed on 6 Jun 1995, now patented, Pat. No. US 5866601 which is a continuation-in-part of Ser. No. US 1995-395245, filed on 27 Feb 1995, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Bosse, Mark L.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 10750
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 26 USPATFULL
TI Enhancing the sensitivity of immunoassay procedures by use of antibodies
directed to the product of a reaction between probe labels and assay substrates

AB The subject invention provides an antibody which specifically binds to the product of a reaction between a labeling substance and a substrate. The subject invention also provides a **method** of making an immunogen used to produce the antibody of the subject invention. The invention further provides methods of using the subject antibody for detecting an antigen of interest in a sample, for example, detecting a protein comprising an amino acid sequence of interest and detecting a nucleic acid molecule comprising a nucleic acid sequence of interest, detecting a polypeptide such as those expressed by infectious agents, fungi or parasites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:81724 USPATFULL
TITLE:	Enhancing the sensitivity of immunoassay procedures by use of antibodies directed to the product of a reaction between probe labels and assay substrates
INVENTOR(S):	Erlanger, Bernard F., Whitestone, NY, United States Chen, Bi-Xing, New York, NY, United States
PATENT ASSIGNEE(S):	The Trustees of Columbia University in the City of New York, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5925532		19990720
APPLICATION INFO.:	US 1997-898583		19970722 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1996-US3549, filed on 14 Mar 1996 which is a continuation-in-part of Ser. No. US 1995-403649, filed on 14 Mar 1995, now patented, Pat. No. US 5650284		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Scheiner, Toni R.		
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dumham LLP		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1245		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 26 USPATFULL

TI Carbocyclic compounds

AB Novel carbocyclic compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:65265 USPATFULL
TITLE:	Carbocyclic compounds
INVENTOR(S):	Bischofberger, Norbert W., San Carlos, CA, United States Kim, Choung U., San Carlos, CA, United States Lew, Willard, San Mateo, CA, United States Liu, Hongtao, Foster City, CA, United States Williams, Matthew A., Foster City, CA, United States
PATENT ASSIGNEE(S):	Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5763483		19980609
APPLICATION INFO.:	US 1996-774345		19961227 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-9306P	19951229 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
LEGAL REPRESENTATIVE: Bosse, Mark L.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 5694
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 26 USPATFULL
TI Biologically active compounds and methods of constructing and using the same
AB A **method** of constructing biologically active compounds which mimic the biological activity of the biologically active protein or which block the activity of the biologically active protein is disclosed. A **method** of identifying specific and discrete portions of pathogen antigens which either serve as epitopes for neutralizing antibodies or which are involved in pathogen binding to host cell receptors is disclosed. A **method** of constructing biologically active compounds which compete with cellular receptors for binding to either biologically active proteins or pathogen antigens is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:49724 USPATFULL
TITLE: Biologically active compounds and methods of constructing and using the same
INVENTOR(S): Greene, Mark I., Penn Valley, PA, United States
Williams, William V., Havertown, PA, United States
Weiner, David B., Merion, PA, United States
Cohen, Jeffrey A., Bala Cynwyd, PA, United States
Kieber-Emmons, Thomas, Newtown Square, PA, United States
Williams, Robert M., Fort Collins, CO, United States
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)
Colorado State University, Fort Collins, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5637677		19970610
APPLICATION INFO.:	US 1992-940654		19920903 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-702833, filed on 20 May 1991, now abandoned which is a continuation of Ser. No. US 1989-326328, filed on 21 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned And a continuation-in-part of Ser. No. US 1990-462542, filed on 9 Jan 1990, now abandoned which is a division of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned And a continuation-in-part of Ser. No. US 1991-648303, filed on 25 Jan 1991, now abandoned which

	is a continuation of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned And a continuation-in-part of Ser. No. US 1991-685881, filed on 15 Apr 1991, now abandoned which is a continuation of Ser. No. US 1990-574391, filed on 27 Aug 1990, now abandoned which is a continuation of Ser. No. US 1988-194026, filed on 13 May 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-74264, filed on 16 Jul 1987, now abandoned And a continuation-in-part of Ser. No. US 1990-583626, filed on 14 Sep 1990, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Cunningham, Thomas M.
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris
NUMBER OF CLAIMS:	35
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 43 Drawing Page(s)
LINE COUNT:	2862

CAS INDEXING IS AVAILABLE FOR THIS PATENT.